Therefore, in patients with diabetic kidney disease and high plasma NT-proBNP concentrations, especially those with NT-proBNP > 416 pg/mL and eGFR > 30 mL/min per 1.73 m2, almost all patients should be actively treated with SGLT2i to improve their cardio-kidney outcomes. Here, NPPB is linked to diabetic kidney disease.